Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care
Abstract
This editorial refers to ‘Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial’†, by J. Butler et al., on page 1203. The presentation of study-specific data is challenging for patients to understand and for physicians to apply, whereas consistent benchmarks of clinically-significant scores and changes in scores are much more readily interpreted. The presentation of study-specific data is challenging for patients to understand and for physicians to apply, whereas consistent benchmarks of clinically-significant scores and changes in scores are much more readily interpreted. Patients with heart failure seek care to not only improve their survival, but also to improve their health status; their symptoms, function, and quality of life. In fact, this latter goal is often most important as it has been previously demonstrated that many patients would trade some of the duration of their survival to improve its quality.1 Yet, despite the importance of health status, clinical trials have been relatively slow in adopting and rigorously testing the impact of new treatments on these outcomes. The recent emphasis by the US Food and Drug Administration (FDA) on patient-reported outcomes (PROs), however, is rectifying this situation,2 and more trials, such as the Empagliflozin and Health Related Quality of Life Outcomes in Patients with Heart Failure with Reduced Ejection Fraction (EMPEROR-Reduced)…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.